Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of DKK 125.17 billion. The enterprise value is 104.36 billion.
| Market Cap | 125.17B |
| Enterprise Value | 104.36B |
Important Dates
The next estimated earnings date is Thursday, February 5, 2026.
| Earnings Date | Feb 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 61.60 million shares outstanding. The number of shares has decreased by -3.12% in one year.
| Current Share Class | 61.60M |
| Shares Outstanding | 61.60M |
| Shares Change (YoY) | -3.12% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 1.15% |
| Owned by Institutions (%) | 53.42% |
| Float | 60.88M |
Valuation Ratios
The trailing PE ratio is 12.72 and the forward PE ratio is 18.03. Genmab's PEG ratio is 3.58.
| PE Ratio | 12.72 |
| Forward PE | 18.03 |
| PS Ratio | 5.11 |
| PB Ratio | 3.42 |
| P/TBV Ratio | 5.39 |
| P/FCF Ratio | 14.80 |
| P/OCF Ratio | 14.37 |
| PEG Ratio | 3.58 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.00, with an EV/FCF ratio of 12.34.
| EV / Earnings | 10.36 |
| EV / Sales | 4.26 |
| EV / EBITDA | 11.00 |
| EV / EBIT | 11.56 |
| EV / FCF | 12.34 |
Financial Position
The company has a current ratio of 6.03, with a Debt / Equity ratio of 0.02.
| Current Ratio | 6.03 |
| Quick Ratio | 6.01 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.10 |
| Debt / FCF | 0.11 |
| Interest Coverage | 54.85 |
Financial Efficiency
Return on equity (ROE) is 29.41% and return on invested capital (ROIC) is 16.02%.
| Return on Equity (ROE) | 29.41% |
| Return on Assets (ROA) | 13.38% |
| Return on Invested Capital (ROIC) | 16.02% |
| Return on Capital Employed (ROCE) | 22.58% |
| Revenue Per Employee | 9.13M |
| Profits Per Employee | 3.76M |
| Employee Count | 2,682 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 17.23 |
Taxes
In the past 12 months, Genmab has paid 1.25 billion in taxes.
| Income Tax | 1.25B |
| Effective Tax Rate | 11.03% |
Stock Price Statistics
The stock price has increased by +32.94% in the last 52 weeks. The beta is 0.79, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | +32.94% |
| 50-Day Moving Average | 1,976.21 |
| 200-Day Moving Average | 1,587.35 |
| Relative Strength Index (RSI) | 57.49 |
| Average Volume (20 Days) | 114,746 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genmab had revenue of DKK 24.48 billion and earned 10.08 billion in profits. Earnings per share was 159.78.
| Revenue | 24.48B |
| Gross Profit | 23.10B |
| Operating Income | 9.03B |
| Pretax Income | 11.33B |
| Net Income | 10.08B |
| EBITDA | 9.38B |
| EBIT | 9.03B |
| Earnings Per Share (EPS) | 159.78 |
Balance Sheet
The company has 21.71 billion in cash and 903.90 million in debt, giving a net cash position of 20.81 billion or 337.81 per share.
| Cash & Cash Equivalents | 21.71B |
| Total Debt | 903.90M |
| Net Cash | 20.81B |
| Net Cash Per Share | 337.81 |
| Equity (Book Value) | 36.61B |
| Book Value Per Share | 594.60 |
| Working Capital | 23.74B |
Cash Flow
In the last 12 months, operating cash flow was 8.71 billion and capital expenditures -257.02 million, giving a free cash flow of 8.46 billion.
| Operating Cash Flow | 8.71B |
| Capital Expenditures | -257.02M |
| Free Cash Flow | 8.46B |
| FCF Per Share | 137.28 |
Margins
Gross margin is 94.36%, with operating and profit margins of 36.87% and 41.17%.
| Gross Margin | 94.36% |
| Operating Margin | 36.87% |
| Pretax Margin | 46.28% |
| Profit Margin | 41.17% |
| EBITDA Margin | 38.30% |
| EBIT Margin | 36.87% |
| FCF Margin | 34.54% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.12% |
| Shareholder Yield | 3.12% |
| Earnings Yield | 8.05% |
| FCF Yield | 6.76% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genmab has an Altman Z-Score of 9.17 and a Piotroski F-Score of 5.
| Altman Z-Score | 9.17 |
| Piotroski F-Score | 5 |